Major deals involving U.S. drugmakers and biotechs over the past decade

Merck's $10 billion acquisition of Verona Pharma signals a strategic imperative among U.S. drugmakers to diversify portfolios and mitigate risks from looming patent expirations, notably for Keytruda. This transaction contributes to a robust M&A environment in the pharmaceutical and biotech sectors, with global deal values reaching $105.3 billion year-to-date in 2025, a 7% increase from the prior year and the highest since 2023. This trend reflects a broader industry drive to secure future growth by acquiring promising therapies across key areas such as oncology, neurology, rare diseases, and obesity.

Analysis

Merck's $10 billion acquisition of Verona Pharma is a strategic move to fortify its respiratory portfolio and diversify revenue streams ahead of the looming patent cliff for its blockbuster drug, Keytruda. This transaction is indicative of a broader, sustained trend across the pharmaceutical industry, where major players are using M&A to address patent expirations and declining sales from legacy products. The data highlights a robust M&A environment, with global deal volume reaching $105.3 billion year-to-date in 2025, a 7% increase from the prior year. This trend is further evidenced by a series of high-value deals over the past decade, including Pfizer's $43 billion acquisition of Seagen to bolster its oncology pipeline and Bristol Myers Squibb's $14 billion purchase of Karuna Therapeutics to secure a new antipsychotic medicine. The consistent pattern of acquiring assets in high-growth areas like oncology, rare diseases, and immunology underscores a clear strategic imperative for large-cap pharma to secure future growth through external innovation.

Key Decisions for Investors

• Investors should evaluate large-cap pharmaceutical firms not only on their internal R&D pipelines but also on their balance sheet capacity and strategic execution of M&A to offset revenue loss from patent expirations.
• The active M&A climate suggests that small-to-mid-cap biotech firms with promising, late-stage therapies in oncology, neurology, and rare diseases represent potential acquisition targets, which may command significant premiums.
• Following a major acquisition, focus should be on the acquirer's ability to successfully integrate the new assets and advance the acquired pipeline, as this is critical to justifying the deal value and realizing long-term growth.